ASH 2024 | ASCEND-CML trial update: frontline asciminib in patients with CP-CML
David Yeung, MBBS, PhD, BSc, FRACP, FRCPA, University of Adelaide, Adelaide, Australia, provides an update on the Australasian Leukaemia and Lymphoma Group (ALLG) CML13 ASCEND-CML trial, a study investigating frontline treatment with asciminib in patients with newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML). Dr Yeung highlights that, when looking at longer-term follow-up data, the deep molecular response (DMR) rate continues to improve, and no new safety signals are reported. Additionally, in the patients who develop treatment resistance, most cases occur due to myristoyl pocket mutations, and these patients can be salvaged with alternative agents. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
